The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation

BACKGROUND: Optimal parathyroid hormone (PTH) control during non-dialysis chronic kidney disease (ND-CKD) might decrease the subsequent risk of parathyroid hyperplasia and uncontrolled secondary hyperparathyroidism (SHPT) on dialysis. However, the evidence for recommending PTH targets and therapeuti...

Descripción completa

Detalles Bibliográficos
Autores principales: Tabibzadeh, Nahid, Karaboyas, Angelo, Robinson, Bruce M, Csomor, Philipp A, Spiegel, David M, Evenepoel, Pieter, Jacobson, Stefan H, Ureña-Torres, Pablo-Antonio, Fukagawa, Masafumi, Al Salmi, Issa, Liang, Xinling, Pisoni, Ronald L, Young, Eric W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771977/
https://www.ncbi.nlm.nih.gov/pubmed/33068419
http://dx.doi.org/10.1093/ndt/gfaa195
_version_ 1783629781531623424
author Tabibzadeh, Nahid
Karaboyas, Angelo
Robinson, Bruce M
Csomor, Philipp A
Spiegel, David M
Evenepoel, Pieter
Jacobson, Stefan H
Ureña-Torres, Pablo-Antonio
Fukagawa, Masafumi
Al Salmi, Issa
Liang, Xinling
Pisoni, Ronald L
Young, Eric W
author_facet Tabibzadeh, Nahid
Karaboyas, Angelo
Robinson, Bruce M
Csomor, Philipp A
Spiegel, David M
Evenepoel, Pieter
Jacobson, Stefan H
Ureña-Torres, Pablo-Antonio
Fukagawa, Masafumi
Al Salmi, Issa
Liang, Xinling
Pisoni, Ronald L
Young, Eric W
author_sort Tabibzadeh, Nahid
collection PubMed
description BACKGROUND: Optimal parathyroid hormone (PTH) control during non-dialysis chronic kidney disease (ND-CKD) might decrease the subsequent risk of parathyroid hyperplasia and uncontrolled secondary hyperparathyroidism (SHPT) on dialysis. However, the evidence for recommending PTH targets and therapeutic strategies is weak for ND-CKD. We evaluated the patient characteristics, treatment patterns and PTH control over the first year of haemodialysis (HD) by PTH prior to HD initiation. METHODS: We studied 5683 incident HD patients from 21 countries in Dialysis Outcomes and Practice Patterns Study Phases 4–6 (2009–18). We stratified by PTH measured immediately prior to HD initiation and reported the monthly prescription prevalence of active vitamin D and calcimimetics over the first year of HD and risk of PTH >600 pg/mL after 9–12 months on HD. RESULTS: The 16% of patients with PTH >600 pg/mL prior to HD initiation were more likely to be prescribed active vitamin D and calcimimetics during the first year of HD. The prevalence of PTH >600 pg/mL 9–12 months after start of HD was greater for patients who initiated HD with PTH >600 (29%) versus 150–300 (7%) pg/mL (adjusted risk difference: 19%; 95% confidence interval : 15%, 23%). The patients with sustained PTH >600 pg/mL after 9–12 months on HD were younger, more likely to be black, and had higher serum phosphorus and estimated glomerular filtration rates at HD initiation. CONCLUSIONS: Increased PTH before HD start predicted a higher PTH level 9–12 months later, despite greater use of active vitamin D and calcimimetics. More targeted PTH control during ND-CKD may influence outcomes during HD, raising the need for PTH target guidelines in these patients.
format Online
Article
Text
id pubmed-7771977
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77719772021-01-05 The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation Tabibzadeh, Nahid Karaboyas, Angelo Robinson, Bruce M Csomor, Philipp A Spiegel, David M Evenepoel, Pieter Jacobson, Stefan H Ureña-Torres, Pablo-Antonio Fukagawa, Masafumi Al Salmi, Issa Liang, Xinling Pisoni, Ronald L Young, Eric W Nephrol Dial Transplant Original Articles BACKGROUND: Optimal parathyroid hormone (PTH) control during non-dialysis chronic kidney disease (ND-CKD) might decrease the subsequent risk of parathyroid hyperplasia and uncontrolled secondary hyperparathyroidism (SHPT) on dialysis. However, the evidence for recommending PTH targets and therapeutic strategies is weak for ND-CKD. We evaluated the patient characteristics, treatment patterns and PTH control over the first year of haemodialysis (HD) by PTH prior to HD initiation. METHODS: We studied 5683 incident HD patients from 21 countries in Dialysis Outcomes and Practice Patterns Study Phases 4–6 (2009–18). We stratified by PTH measured immediately prior to HD initiation and reported the monthly prescription prevalence of active vitamin D and calcimimetics over the first year of HD and risk of PTH >600 pg/mL after 9–12 months on HD. RESULTS: The 16% of patients with PTH >600 pg/mL prior to HD initiation were more likely to be prescribed active vitamin D and calcimimetics during the first year of HD. The prevalence of PTH >600 pg/mL 9–12 months after start of HD was greater for patients who initiated HD with PTH >600 (29%) versus 150–300 (7%) pg/mL (adjusted risk difference: 19%; 95% confidence interval : 15%, 23%). The patients with sustained PTH >600 pg/mL after 9–12 months on HD were younger, more likely to be black, and had higher serum phosphorus and estimated glomerular filtration rates at HD initiation. CONCLUSIONS: Increased PTH before HD start predicted a higher PTH level 9–12 months later, despite greater use of active vitamin D and calcimimetics. More targeted PTH control during ND-CKD may influence outcomes during HD, raising the need for PTH target guidelines in these patients. Oxford University Press 2020-10-17 /pmc/articles/PMC7771977/ /pubmed/33068419 http://dx.doi.org/10.1093/ndt/gfaa195 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Articles
Tabibzadeh, Nahid
Karaboyas, Angelo
Robinson, Bruce M
Csomor, Philipp A
Spiegel, David M
Evenepoel, Pieter
Jacobson, Stefan H
Ureña-Torres, Pablo-Antonio
Fukagawa, Masafumi
Al Salmi, Issa
Liang, Xinling
Pisoni, Ronald L
Young, Eric W
The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation
title The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation
title_full The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation
title_fullStr The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation
title_full_unstemmed The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation
title_short The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation
title_sort risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771977/
https://www.ncbi.nlm.nih.gov/pubmed/33068419
http://dx.doi.org/10.1093/ndt/gfaa195
work_keys_str_mv AT tabibzadehnahid theriskofmedicallyuncontrolledsecondaryhyperparathyroidismdependsonparathyroidhormonelevelsathaemodialysisinitiation
AT karaboyasangelo theriskofmedicallyuncontrolledsecondaryhyperparathyroidismdependsonparathyroidhormonelevelsathaemodialysisinitiation
AT robinsonbrucem theriskofmedicallyuncontrolledsecondaryhyperparathyroidismdependsonparathyroidhormonelevelsathaemodialysisinitiation
AT csomorphilippa theriskofmedicallyuncontrolledsecondaryhyperparathyroidismdependsonparathyroidhormonelevelsathaemodialysisinitiation
AT spiegeldavidm theriskofmedicallyuncontrolledsecondaryhyperparathyroidismdependsonparathyroidhormonelevelsathaemodialysisinitiation
AT evenepoelpieter theriskofmedicallyuncontrolledsecondaryhyperparathyroidismdependsonparathyroidhormonelevelsathaemodialysisinitiation
AT jacobsonstefanh theriskofmedicallyuncontrolledsecondaryhyperparathyroidismdependsonparathyroidhormonelevelsathaemodialysisinitiation
AT urenatorrespabloantonio theriskofmedicallyuncontrolledsecondaryhyperparathyroidismdependsonparathyroidhormonelevelsathaemodialysisinitiation
AT fukagawamasafumi theriskofmedicallyuncontrolledsecondaryhyperparathyroidismdependsonparathyroidhormonelevelsathaemodialysisinitiation
AT alsalmiissa theriskofmedicallyuncontrolledsecondaryhyperparathyroidismdependsonparathyroidhormonelevelsathaemodialysisinitiation
AT liangxinling theriskofmedicallyuncontrolledsecondaryhyperparathyroidismdependsonparathyroidhormonelevelsathaemodialysisinitiation
AT pisonironaldl theriskofmedicallyuncontrolledsecondaryhyperparathyroidismdependsonparathyroidhormonelevelsathaemodialysisinitiation
AT youngericw theriskofmedicallyuncontrolledsecondaryhyperparathyroidismdependsonparathyroidhormonelevelsathaemodialysisinitiation
AT tabibzadehnahid riskofmedicallyuncontrolledsecondaryhyperparathyroidismdependsonparathyroidhormonelevelsathaemodialysisinitiation
AT karaboyasangelo riskofmedicallyuncontrolledsecondaryhyperparathyroidismdependsonparathyroidhormonelevelsathaemodialysisinitiation
AT robinsonbrucem riskofmedicallyuncontrolledsecondaryhyperparathyroidismdependsonparathyroidhormonelevelsathaemodialysisinitiation
AT csomorphilippa riskofmedicallyuncontrolledsecondaryhyperparathyroidismdependsonparathyroidhormonelevelsathaemodialysisinitiation
AT spiegeldavidm riskofmedicallyuncontrolledsecondaryhyperparathyroidismdependsonparathyroidhormonelevelsathaemodialysisinitiation
AT evenepoelpieter riskofmedicallyuncontrolledsecondaryhyperparathyroidismdependsonparathyroidhormonelevelsathaemodialysisinitiation
AT jacobsonstefanh riskofmedicallyuncontrolledsecondaryhyperparathyroidismdependsonparathyroidhormonelevelsathaemodialysisinitiation
AT urenatorrespabloantonio riskofmedicallyuncontrolledsecondaryhyperparathyroidismdependsonparathyroidhormonelevelsathaemodialysisinitiation
AT fukagawamasafumi riskofmedicallyuncontrolledsecondaryhyperparathyroidismdependsonparathyroidhormonelevelsathaemodialysisinitiation
AT alsalmiissa riskofmedicallyuncontrolledsecondaryhyperparathyroidismdependsonparathyroidhormonelevelsathaemodialysisinitiation
AT liangxinling riskofmedicallyuncontrolledsecondaryhyperparathyroidismdependsonparathyroidhormonelevelsathaemodialysisinitiation
AT pisonironaldl riskofmedicallyuncontrolledsecondaryhyperparathyroidismdependsonparathyroidhormonelevelsathaemodialysisinitiation
AT youngericw riskofmedicallyuncontrolledsecondaryhyperparathyroidismdependsonparathyroidhormonelevelsathaemodialysisinitiation